Renal failure in end-stage liver disease and liver transplantation

International Anesthesiology Clinics

Volumn 44, Issue 3, 2006, Pages 35-49

  Planinsic, Raymond M ^a   Lebowitz, Jonathan J ^b  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FAILURE; LABORATORY TEST; LIVER DISEASE; LIVER TRANSPLANTATION; MORTALITY; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URINALYSIS; DRUG ANTAGONISM; HEPATORENAL SYNDROME; LIVER FAILURE; PEROPERATIVE CARE; PEROPERATIVE COMPLICATION;

CALCINEURIN;

CALCINEURIN; HEPATORENAL SYNDROME; HUMANS; INTRAOPERATIVE CARE; INTRAOPERATIVE COMPLICATIONS; KIDNEY FAILURE; LIVER FAILURE; LIVER TRANSPLANTATION;

EID: 33747491501     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000210807.24298.f7     Document Type: Review

References (83)

1. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35:1179-1185.
2. Gonwa TA, Klintmalm GB, Levy M, et al. Impact of pretransplant renal function on survival after transplantation. Transplantation. 1995;59:361-365.
3. Brown RSJ, Lombardero M, Lake JR. Outcome in patients with renal insufficiency undergoing liver or liver kidney transplantation. Transplantation. 1996;62:1788-1793.
4. Ring-Larsen H, Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types and prognosis. Gut. 1981;22:585-591.
5. McCauley J, Van Thiel DH, Starzl TE, et al. Acute and chronic renal failure in liver transplantation. Nephron. 1990;55:121-128.
6. Bilbao I, Charco R, Balsells J, et al. Risk factors of acute renal failure requiring dialysis after liver transplantation. Clin Transpl. 1998;12:123-129.
7. Distant DA, Gonwa TA. The kidney in liver transplantation. J Am Soc Nephrol. 1993;4:129-136.
8. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med. 1987;82(abstract):945.
9. Hiesse C, Samuel D, Bensadoun H, et al. Combined liver and kidney transplantation in patients with chronic nephritis associated with end-satge liver disease. Nephrol Dial Transpl. 1995;10(Suppl 6):129-133.
10. Davis CL, Gonowa TA, Wilkinson AH. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl. 2002;8:91-109.
11. Dimashkieh H, Koehler A. Primary hyperoxaluria affecting the liver. Arch Pathol Lab Med. 2002;126:1250-1251.
12. Cibrik DM, Kaplan B, Arndorfer JA, et al. Renal allograft survival in patients with oxalosis. Transplantation. 2002;74:707-710.
13. Gagnadoux MF, Lacaille F, Niaudet P, et al. Long term results of liver-kidney transplantation in children with primary hyperoxaluria. Pediatr Nephrol. 2001;16:946-950.
14. Shapiro R, Weismann I, Mandel H, et al. Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation. 2001;72:428-432.
15. Fraley DS, Burr R, Bernardini J, et al. Impact of acute renal failure on mortality in end-stage liver disease with or without transplant. Kidney Int. 1998;54:518-524.
16. Esson ML, Schrier RW. Diagnosis and treatment of acute tubular necrosis. Ann Intern Med. 2002;137:744-752.
17. Biswas KD, Jain AK. Hepatorenal syndrome. Trop Gastroenterol. 2002;23:113-116.
18. Eisenman A, Armali Z, Enat R, et al. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med. 1999;246:183-190.
19. McDiarmid SV. Renal function in pediatric liver transplant patients. Kidney Int Suppl. 1996;53:S77-S84.
20. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol. 2002;17:739-747.
21. Epstein M. Renal function in liver disease. In: Greenberg A, ed. Primer on Kidney Diseases. 2nd ed. San Diego: Academic Press; 1998:188-189.
22. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36(4 Part 1):941-948.
23. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002;14:153-158.
24. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930.
25. Mulkay JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001;64:15-19.
26. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870-875.
27. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164-176.
28. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233-243.
29. Angeli P, Valpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690-1697.
30. Grobecker HF, Kees F. Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. Int Angiol. 1993;12:119-124.
31. Di Campli C, Zileri Dal Verme L, Andrisani MC, et al. Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure. Curr Med Chem. 2003;10:341-348.
32. Sen S, Felldin M, Steiner C, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's diseasae. Liver Transpl. 2002;8:962-967.
33. Shi Y, He J, Chen S, et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning - a case report. Liver. 2002;22(Suppl 2):78-80.
34. Schachschal G, Morgera S, Kupferling S, et al. Emerging indications for MARS dialysis. Liver. 2002;22(Suppl 2):63-68.
35. Mullhaupt B, Kullak-Ublick GA, Ambuhl P, et al. First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure. Liver. 2002; 22(Suppl 2):59-62.
36. Novelli G, Rossi M, Pretagostini R, et al. MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of scute liver failure. Liver. 2002;22(Suppl 2):43-47.
37. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver. 2002;22(Suppl 2):20-25.
38. Kellum J, Johnson J, Kramer D, et al. Diffuse vs. convective therapy: effects of mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med. 1998;26:1995-2000.
39. Pascual E, Gomez-Arnau J, Pensado A, et al. Incidence and risk factors of early acute renal failure in liver transplant patients. Transplant Proc. 1993;25:1827.
40. Ishitani M, Wilkowski M, Stevenson W, et al. Outcome of patients requiring hemodialysis after liver transplantation. Transplant Proc. 1993;25:1762-1763.
41. Byrick RJ, Rose DK. Pathophysiology and prevention of acute renal failure: the role of the anaesthetist. Can J Anaesth. 1990;37(4 Part 1):456-467.
42. Goldfinger D. Acute hemolytic transfusion reactions - a fresh look at pathogenesis and considerations regarding therapy. Transfusion. 1977;17:85-98.
43. Hilberman M, Maseda J, Stinson EB, et al. The diuretic properties of dopamine in patients after open heart operation. Anesthesiology. 1984;61:489-494.
44. Polson RJ, Park GR, Lindop MJ, et al. The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia. 1987;42:15-19.
45. Swygert TH, Roberts LC, Valek TR, et al. Effect of introperative low-dose dopamine on renal function in liver transplant recipients. Anesthesiology. 1991;75:571-576.
46. Merin RG, Bastron RD. Diuretics. In: Smith NT, Miller RD, Corbascio AN, eds. Drug Interactions in Anesthesia. Philadelphia: Lea and Febiger; 1986:206-224.
47. Tonnesen AS. Clinical pharmacology and use of diuretics. In: Hershey BJ, Bamforth BJ, Zauder HS, eds. Review Courses in Anesthesiology. Philadelphia: JB Lippincott Co; 1983:217-226.
48. Szwed JJ, Kleit SA, Hamburger RJ. Effect of furosemide and chlorthiazide on the thoracic duct lymph flow in the dog. J Lab Clin Med. 1972;79:693-700.
49. Driscoll DF, Pinson CW, Jenkins RL, et al. Potential protective effects of furosemide against early cyclosporine-induced renal injury in hepatic transplant recipients. Transplant Proc. 1989;21:3549-3550.
50. Planinsic RM, De Wolf AM, Kang Y, et al. Dopamine, furosemide and mannitol infusions and the incidence of renal dysfunction after orthotopic liver transplantation. Anesthesiology. 1996;85(3A):A247.
51. Planinsic RM, Kang Y, De Wolf AM, et al. Dopamine, furosemide and mannitol infusions and changes in serum creatinines after liver transplantation. Liver Transpl Surg. 1997;3:C40.
52. Dlewati A, Lokhandwala MF. Dose response analysis of the effects of fenoldopam, a dopamine-1 receptor agonist on renal function. Drug Dev Res. 1991;22:59-68.
53. Fontana I, Germi MR, Beatini M, et al. Dopamine "renal dose" versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation. Transplant Proc. 2005;37:2474-2475.
54. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis. 2005;46:26-34.
55. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation. 2005;111:3230-3235.
56. Bromley PN, Cottam SJ, Hilmi I, et al. Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. BJA. 1995;75:352-354.
57. Thies JC, Koeppel TA, Lehmann T, et al. Efficacy of N-acetylcysteine as hepatoprotective agent in liver transplantation; an experimental study. Transplant Proc. 1997;29:1326-1327.
58. Suleyman D, Mine JE. Pentoxifyline and N-acetylcysreine in hepatic ischemia reperfusion injury. Clin Chim Acta. 1998;275:127-135.
59. Thies JC, Teklote J, Clauer U, et al. The efficacy of NAC as a hepatoprotective agent in liver transplantation. Transplant Int. 1998;11(Suppl 1):S390-S392.
60. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reduction in renal dysfunction by N-acetylcysteine. N Engl J Med. 2000;343:180-184.
61. Cotterell AH, Fischer RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transl. 2002;16(Suppl 7):49-51.
62. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation. 2002;74:1560-1567.
63. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int. 1999;55:674-685.
64. Jurewicz WA. Tracolimus versus cyclosporine immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant. 2003;18(Suppl 1):I7-11.
65. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510.
66. Cardarelli F, Saidman S, Theruvath T, et al. The problem of late allograft loss in kidney transplantation. Minerva Urol Nefrol. 2003;55:1-11.
67. Rerolle JP, Akposso K, Lerolle N, et al. Tacrolimus-induced hemolytic uremic syndrome and end stage renal failure after liver transplantation. Clin Transplant. 2000;14:262-265.
68. Evens AM, Kwann HC, Kaufman DB, et al. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation. 2002;74:885-887.
69. Yango A, Morrissey P, Monaco A, et al. Successful treatment of tacrolimus-associated thrombotic microagiopathy with sirolimus conversion and plasma exchange. Clin Nephrol. 2002;58:77-78.
70. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenia purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8:286-293.
71. Holman MJ, Gonwa TA, Cooper B, et al. FK506 associated thrombotic thrombocytopenic purpura. Transplantation. 1993;55:205-206.
72. Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantationin primary hyperoxaluria. Liver Transplant. 2001;7:954-963.
73. Burch J, Moore F, Franciose R. The abdominal compartment syndrome. Surg Clin North Am. 1996;76:833-842.
74. Malbrain M. Abdominal pressure in the critically ill patients. Intensive Care Med. 1999;25:1453-1458.
75. Cullen DJ, Coyle JP, Teplick R, et al. Cardiovascular, pulmonary and renal effects of massively increased intra-abdominal pressure in critically ill patients. Crit Care Med. 1989;17:118-121.
76. Biancofiore G, Bindi ML, Romanelli AM, et al. Intra-abdominal pressure monitoring in liver transplant recipients: a prospective study. Intensive Care Med. 2003;29:30-36.
77. Tsai JD, Lee HC, Lin CC, et al. Epstein-Barr virus-associated acute renal failure: diagnosis, treatment and follow-up. Pediatr Nephrol. 2003;18:667-674.
78. Collins MH, Montone KT, Leahey AM, et al. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics. 2001;107:E89.
79. Iwamoto S, Azuma E, Hori H, et al. BK virus-associated fatal renal failure following late-onset hemorrhagic cystitis in an unrelated bone marrow transplant. Pediatr Hematol Oncol. 2002;19:255-261.
80. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipiets. N Engl J Med. 2002;347:488-496.
81. Elli A, Banfi G, Fogazzi GB, et al. BK polyomavirus interstitial nephritis in a renal transplant patient with no previous acute rejection episodes. J Nephrol. 2002;15:313-316.
82. Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant. 2002;2:25-30.
83. Marshall WF, Telenti A, Proper J, et al. Survey of urine from transplant recipients for polyomavirus JC and BK using the polymerase chain reaction. Mol Cell Probes. 1991;5:125-128.